Study of Urinary N-Acetyl-Beta-D-Glucosaminidase as a biomarker of Diabetic Nephropathy

Mahmoud, Amira A.; Mostafa, Noha M; Mesbah, Osama; Sabry, Omar M.; Al-Barshomy, Said M

doi:10.21608/ejhm.2021.142879

Cited by 2 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a healthy state, cause NAG has a large molecular weight and cannot normally pass through glomerular filtration, the renal tubules in the early stage of DN can still absorb the excessive proteinuria of glomerular filtration. Urine albumin in this stage is normal, but the expression of NAG increases, which may be due to the strengthening of reabsorption by the renal proximal convoluted tubule, the high protein content in the renal proximal convoluted tubule stimulating the reabsorption system, activation of mitochondrial lysosomal enzyme, and increased lysosomal enzyme density, the large release of lytic enzyme and the leakage of lysosomal enzyme[ 33 - 35 ]. The results of this study showed that compared with the data of age, gender, duration of diabetes, combined hyperlipidemia and combined hypertension in the two groups, the expression of urinary NAG and serum RBP in group B was higher than that in group A, suggesting that the expression of serum RBP and urinary NAG may be the cause of disease progression to DN in patients with T2DM.…”

Section: Discussionmentioning

confidence: 99%

Application of urinary N-acetyl-β-D-glucosaminidase combined with serum retinol-binding protein in early detection of diabetic nephropathy

Lin¹,

Dai²,

Zhao³

et al. 2023

World J Diabetes

View full text Add to dashboard Cite

BACKGROUND Diabetic nephropathy (DN) is a microangiopathy of type 2 diabetes mellitus (T2DM), which can damage the kidney through various ways and mechanisms due to the nature of the disease, involving the renal interstitium and glomeruli. However, in the early stage of the disease, patients only showed kidney volume increase and glomerular hyperthyroidism, and typical symptoms that are difficult to arouse individual attention were noticed. AIM To observe the expression of serum retinol-binding protein (RBP) and urinary N-acetyl-β-D-glucosaminidase (NAG) in patients with DN, and to analyze their value in disease prediction, so as to provide new targets for early diagnosis and treatment of DN. METHODS The baseline data of 50 T2DM patients treated in our hospital between January 2021 and December 2022 were retrospectively reviewed and included in group A. The baseline data of 50 patients with type 2 DN admitted to our hospital during the same period were collected and included in group B. The baseline data and serum RBP and urine NAG expression were compared between the two groups to analyze their value in the early prediction of DN. RESULTS There was no significant difference in age, gender, duration of diabetes, combined hyperlipidemia and combined hypertension between the two groups ( P > 0.05); the expression of urinary NAG and serum RBP in group B was higher than that in group A, and the difference was statistically significant ( P < 0.05); a multiple logistic regression model was established, and the results showed that urinary NAG and serum RBP were related to the presence or absence of injury in diabetic patients, and overexpression of urinary NAG and serum RBP may be risk factors for renal injury in T2DM patients (OR > 1, P < 0.05); receiver operating curve curve was plotted, and the results showed that the area under the curve of urinary NAG and serum RBP expression alone and in combination for predicting DN was > 0.80, and the predictive value was satisfactory; bivariate Spearman linear correlation analysis showed that there was a positive correlation between urinary NAG and serum RBP expression in patients with DN ( r = 0.566, P = 0.000). CONCLUSION The increased expression of urinary NAG and serum RBP may be the risk factors leading to the progression of T2DM to DN. The possibility of DN can be considered in patients with urinary NAG and serum RBP overexpression by examining the expression of urinary NAG and serum RBP in patients with T2DM in clinical practice.

show abstract

Section: Discussionmentioning

confidence: 99%

Application of urinary N-acetyl-β-D-glucosaminidase combined with serum retinol-binding protein in early detection of diabetic nephropathy

Lin¹,

Dai²,

Zhao³

et al. 2023

World J Diabetes

View full text Add to dashboard Cite

show abstract

“…CKD biomarkers are essential for the diagnosis and follow-up of kidney diseases. These biomarkers include (a) conventional CKD biomarkers like serum creatinine and proteinuria and (b) Molecular biomarkers includes N-acetyl-D-glucosaminidase (NAG) [8], kidney injury molecule-1 (KIM-1) [9], neutrophil gelatinase-associated lipocalin (NGAL) [10], cystatin C (Cys C) [11], and so on. Molecular biomarkers have garnered significant recognition in recent years for their precise and early diagnostic capabilities in identifying kidney disease.…”

Section: Introductionmentioning

confidence: 99%

A brief review on the nanomaterials-based detection of CKD biomarkers

Bhatt,

Kukkar

2024

E3S Web Conf.

View full text Add to dashboard Cite

Chronic kidney disease (CKD) imposes a significant worldwide medical burden, exacerbated by the often limited efficacy of current treatments. The future prevention and management of CKD critically rely on early detection and effective intervention. Nanomaterials (NMs), such as fluorescence carbon dots (CDs), quantum dots (QDs), and metal-based NMs, emerge as unique and highly sensitive probe materials expected to play a substantial role in the precise identification of CKD biomarkers. NMs’ design makes it possible to manage properties including size, shape, charge, and targeting ligands, which enhances the biological compatibility and availability of medicines. Consequently, the rise of NMs in medicine has brought about fresh approaches to CKD diagnosis. This review explores the utility of the NMs for the rapid identification of CKD biomarkers.

show abstract

Study of Urinary N-Acetyl-Beta-D-Glucosaminidase as a biomarker of Diabetic Nephropathy

Cited by 2 publications

References 9 publications

Application of urinary N-acetyl-β-D-glucosaminidase combined with serum retinol-binding protein in early detection of diabetic nephropathy

Application of urinary N-acetyl-β-D-glucosaminidase combined with serum retinol-binding protein in early detection of diabetic nephropathy

A brief review on the nanomaterials-based detection of CKD biomarkers

Contact Info

Product

Resources

About